Limitations
Short-term follow-up and small sample size were among the barriers that
limited the present study. Hence, to increase the accuracy rate of the
findings in the detection of the postpartum hemorrhages, other
researchers are recommended not only to assess the severity or volume of
the hemorrhage but also, they are also encouraged to analyze the mean
number of days with hemorrhage throughout the intervention.
Conclusion
Outpatient treatment in patients with miscarriage can be carried out by
the administration of oxytocin and methylergometrine in combination with
misoprostol. This form of medical therapy has demonstrated positive
impacts on the expulsion of retained products of conception (RPOC)
during the first trimester and was more cost-effective compared to
surgical and hospitalization approaches. Moreover, outpatient treatments
in cases of medical abortion and avoidance of hospitalization are
advantageous, especially during the Covid-19 pandemic. Not only it
preserves the medical care resources, service management, and
effectively improve women’s status of physical and mental health, but it
is also more convenient for the patients to manage the pain at ease as
they receive psychological support from their families at home. Besides,
these patients with outpatient treatment often find the opportunity to
handle housework affairs and can also meet other children’s needs at
home. Thereby, patients’ tendency toward outpatient treatments motivated
us to apply certain therapeutic methods to manage intrauterine fetal
death during the first trimester. We believe that this medical therapy
is more cost-effective and it is a safer therapeutic approach for the
patients compared to surgical methods. Thus, we suggest all medical
experts continue with outpatient treatment.
Declarations
Ethical approval of the
study
Written inform consent was obtained from the patients in our study. The
purpose of this research was completely explained to the patient and was
assured that their information will be kept confidential by the
researcher. This research was approved by the ethical committee of
Jahrom University of Medical Sciences issued with code No.:
IR.JUMS.REC.1396.143, and it was further registered in the Iranian
registry of clinical trials with code ID of IRCT20200122046221N1.
Consent for publication
Consent was obtained from the patients regarding the publication of this
study.
Availability of data and materials
SPSS data of the participant can be requested from the authors. Please
write to the corresponding author if you are interested in such data.
Competing interests
The authors declare that they have no competing interests.
Funding
No financial support was received for this study.
Acknowledgments
We would like to express our sincere gratitude to the Clinical Research
Development Unit of Peymanieh Educational and Research and Therapeutic
Center affiliated to Jahrom University of Medical Sciences for
providing suitable environmental facilities and research requirements.
Authors contribution
AR designed the study. AM and ZZ collected the data, NT drafted the
manuscript and RS revised and edited the manuscript. All authors proof
read and approved the final version of the manuscript.
References
1. Obstetricians, A.C.o. and Gynecologists, ACOG Committee Opinion No.
427: Misoprostol for postabortion care. Obstet. Gynecol, 2009. 113(2 Pt
1): p. 465.
2. Say, L., et al., Global causes of maternal death: a WHO systematic
analysis. Lancet Glob. Health, 2014. 2(6): p. e323-e333.
3. Jones, R.K. and J. Jerman, Abortion incidence and service
availability in the United States, 2014. Perspect. Sex. Reprod. Health,
2017. 49(1): p. 17-27.
4. Hooker, A.B., et al., Long-term complications and reproductive
outcome after the management of retained products of conception: a
systematic review. Fertil. Steril., 2016. 105(1): p. 156-164. e2.
5. Ambusaidi, Q. and A. Zutshi, Effectiveness of Misoprostol for
Induction of First-Trimester Miscarriages: Experience at a single
tertiary care centre in Oman. Sultan Qaboos Univ. Med. J, 2015. 15(4):
p. e534.
6. Raymond, E.G., et al., Mortality of induced abortion, other
outpatient surgical procedures and common activities in the United
States. Contraception, 2014. 90(5): p. 476-479.
7. Thiebaut, M., et al., Retrospective assessment of the influence of
gestational age on the first trimester medical abortion efficiency. Rev
Med Liege, 2017. 72(4): p. 193-198.
8. Ibiyemi, K.F., A.I. Munir’deen, and K.T. Adesina, Randomised Trial of
Oral Misoprostol Versus Manual Vacuum Aspiration for the Treatment of
Incomplete Abortion at a Nigerian Tertiary Hospital. Sultan Qaboos Univ.
Med. J, 2019. 19(1): p. e38.
9. Hernández-Martínez, A., et al., Oxytocin discontinuation after the
active phase of induced labor: A systematic review. Women Birth, 2019.
32(2): p. 112-118.
10. Budden, A., L.J. Chen, and A. Henry, High‐dose versus low‐dose
oxytocin infusion regimens for induction of labour at term. Cochrane
Database Syst. Rev, 2014(10).
11. Schaider, J.J., et al., Rosen & Barkin’s 5-minute emergency
medicine consult. Vol. 4. 2012: Lippincott Williams & Wilkins.
12. Kaviani, M., et al., Comparison of the Effects of Simultaneous Use
of Methylergonovine and Combined Low-dose (LD) Contraceptive Pills on
Hemorrhage Due to Retained Pregnancy Products after Abortion. Int. J.
Curr. Microbiol. App. Sci, 2016. 5(11): p. 499-507.
13. Paris, A.E., et al., Mifepristone and misoprostol compared to
osmotic dilators for cervical preparation prior to surgical abortion at
15–18 weeks’ gestation: a randomised controlled non-inferiority trial.
BMJ Sex. Reprod. Health, 2020. 46(1): p. 67-72.
14. Guilbert, E.R., et al., First-trimester medical abortion practices
in Canada: National survey. Can Fam Physician, 2016. 62(4): p.
e201-e208.
15. Whitehouse, K., et al., Use of medications to decrease bleeding
during surgical abortion: a survey of abortion providers’ practices in
the United States. Contraception, 2018. 97(6): p. 500-503.
16. Jahangir, M., et al., Efficacy of vaginal Misoprostol for
terminating missed abortion. KAUMS Journal (FEYZ), 2005. 9(2): p. 1-5.
17. Wewers, M.E. and N.K. Lowe, A critical review of visual analogue
scales in the measurement of clinical phenomena. Res Nurs Health, 1990.
13(4): p. 227-236.
18. Feng, X., et al., Transcutaneous acupoint electrical stimulation
pain management after surgical abortion: A cohort study. Int J Surg,
2016. 30: p. 104-108.
19. Conti, J.A., et al., Self-administered lidocaine gel for pain
control with first-trimester surgical abortion. Obstetrics &
Gynecology, 2016. 128(2): p. 297-303.
20. Thaxton, L., et al., Nitrous Oxide Compared with Intravenous
Sedation for Second-Trimester Abortion: A Randomized Controlled Trial.
Obstetrics & Gynecology, 2018. 132(5): p. 1192-1197.
21. Rezvani Amin, M., et al., Correlation between visual analogue scale
and short form of McGill questionnaire in patients with chronic low back
pain. Qom University of Medical Sciences Journal, 2011. 5(1): p. 31-34.
22. Petca, A., et al., second trimester abortion: mifepristone plus
misoprostol vs. misoprostol plus oxytocin. Farmacia, 2019. 67(5): p.
850-856.
23. Bakker, R., S. Pierce, and D. Myers, The role of prostaglandins E1
and E2, dinoprostone, and misoprostol in cervical ripening and the
induction of labor: a mechanistic approach. Arch Gynecol Obstet, 2017.
296(2): p. 167-179.
24. Huffmeijer, R., et al., Salivary levels of oxytocin remain elevated
for more than two hours after intranasal oxytocin administration. Neuro
endocrinology letters, 2012. 33(1): p. 21-25.
25. Tehranian, A., et al., The effect of adding hyoscine to vaginal
misoprostol on abortion induction success rate. Tehran Univ. Med. J,
2010. 68(4).
26. Niroumanesh, S. and N. Azadbeh, Use of vaginal Misoprostol tablets
in the management of missed abortion in pregnant women. J Adv Med Biomed
Res, 2002. 10(341):p 1-7.
27. Ghasemi, M., et al., Comparison of two dosing regimens of
intravaginal misoporostol for second-trimester abortion. The Iranian
Journal of Obstetrics, Gynecology and Infertility, 2018. 21(4): p.
19-24.
28. Sang, G.-w., et al., Termination of early pregnancy by two regimens
of mifepristone with misoprostol and mifepristone with PG05—a
multicentre randomized clinical trial in China. Contraception, 1994.
50(6): p. 501-510.
29. Jain, R., et al., Comparison of intramuscular methylergometrine,
rectal misoprostol, and low-dose intravenousoxytocin in active
management of the third stage of labor. Tzu Chi Med. J., 2019. 31(3): p.
158.
30. Tan, J., et al., Misoprostol versus ergometrine‐oxytocin for
preventing postpartum haemorrhage: a systematic review and meta‐analysis
of randomized controlled trials. Evid Based Med, 2016. 9(4): p. 194-204.
31. Dabbaghi Gale, T., et al., Comparison of intravenous oxytocin and
oral misoprostol in reduction of postpartum hemorrhage. ZUMS Journal,
2012. 20(81): p. 1-8.
32. Whitehouse, K., et al., Effects of prophylactic oxytocin on bleeding
outcomes in women undergoing dilation and evacuation: a randomized
controlled trial. Obstetrics & Gynecology, 2019. 133(3): p. 484-491.
33. Huh, W.K., D. Chelmow, and F.D. Malone, A double-blinded, randomized
controlled trial of oxytocin at the beginning versus the end of the
third stage of labor for prevention of postpartum hemorrhage. Gynecol
Obstet Invest, 2004. 58(2): p. 72-76.
34. Cunningham F. G., Norman F. G., KennethJ. L., et al. abortion.
Williams obstetrics. 21th Edition. New York, MC Graw Hill.2001; pp:
855-883.
35. Fiala, C., et al., Pain during medical abortion, the impact of the
regimen: a neglected issue? A review. Eur J Contracept Reprod Health
Care, 2014. 19(6): p. 404-419.
36. Fiala, C., et al., Pain management for up to 9 weeks medical
abortion–An international survey among abortion providers. Eur. J.
Obstet. Gynecol, 2018. 225: p. 181-184.
37. Suhonen, S., et al., Pain during medical abortion: predicting
factors from gynecologic history and medical staff evaluation of
severity. Contraception, 2011. 83(4): p. 357-361.
38. Kemppainen, V., et al., Pain during medical abortion inearly
pregnancy in teenaged and adult women. Acta Obstet Gynecol Scand, 2020.
39. Braaten, K.P., et al., A randomized comparison of intravenous
sedation using a dosing algorithm compared to standard care during
first-trimester surgicalabortion. Contraception, 2018. 97(6): p.
490-496.
40. Niño-Maldonado, A.I., et al., Efficacy and tolerability of
intravenous methylergonovine in migraine female patients attending the
emergency department: a pilot open-label study. Head Face Med, 2009.
5(1): p. 21.
Table 1. Demographic variables in drug prescription based on
mean and standard deviation